Antag Therapeutics ApS, a Denmark-based privately-held biotechnology company, announced on Thursday that it has named Dr Christine Fischette as its new director.
Dr Fischette has more than 30 years of pharmaceutical experience. She has held strategic and operational roles within research, drug development, commercialisation and business development at Hoffman-LaRoche, Pfizer and Novartis. She has worked on multiple private company Business/Scientific Advisory Boards for therapeutics and devices. She has served as executive director/senior advisor at the boutique biopharma investment banks Torreya Partners and Griffin Securities.
Dr Fischette has a BA in Biology Education from Rutgers University and a PhD in Physiology from Rutgers Biomedical Health Sciences, formerly known as the University of Medicine and Dentistry of New Jersey.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer